Home
Obi Profile
Fees
Services
News
Publications
Contact
You are here:
Title Details
Search
Login
PHARMACEUTICAL COMPOSITIONS TO REDUCE COMPLICATIONS OF OCULAR STEROID
No-Receipt date
2018-01996 - 11/06/2018
No-Filing date
20180401574 - 11/06/2018
No-Granting date
3096060 - 03/08/2018
No-EPO application date
13747021.7 - 08/02/2013
No-EPO granting date
2797601 - 21/03/2018
Gazette No-Publication date of application
-
Gazette No-Publication date of granted patent
8/2018 - 31/10/2018
Expiration date
09/02/2033
Kind of title
Validation of European Patent
Legal status
VALID
Priorities
US201261597189 P10/02/2012/US
Active Substance of Supplementary Certificates
-
IPC Classification
Ipc Class
A61K 31/56
A61K 31/661
A61K 31/685
A61K 9/08
A61P 27/02
Related Documents
Related Titles
Owners
Code
Firstname
Surname
Address
Town
ZIP
Country
882001
TAIWAN LIPOSOME COMPANY, LTD.
11F-1 NO 3 YUANQU STREET NANGANG DISTRICT
TAIPEI CITY
SEPARATE CUSTOMS TERRITORY OF TAIWAN, PENGHU, KIMMEN AND MATSU
882002
TLC BIOPHARMACEUTICALS, INC.
432 NORTH CANAL STREET 20
SOUTH SAN FRANCISCO, CA 94080
UNITED STATES OF AMERICA (USA)
Inventors
Code
Firstname
Surname
2192859
HONG, KEELUNG
2192860
GUO, LUKE S.S.
2192861
TSENG, YUN-LONG
2192862
SHIH, SHEUE-FANG
2192863
CHANG, PO-CHUN
2192864
TSAI, CHIH-CHIANG
2192865
LIN, HONG-HUI
Representatives
Code
Firstname
Surname
Address
Town
Zip
3463
MARIA
ATHANASIADOU "ELENI G. PAPAKONSTANTINOU KAI SYNERGATES, DIKIGORIKI ETAIRIA"
KOUMPARI 2
ATHINA (ATTIKIS)
10674
Contact
Code
Firstname
Surname
Address
Town
Zip
Country
848
EFANGELIA
GIAZITZOGLOU - THOMAIDOU
KOUMPARI 2
ATHINA (ATTIKIS)
10674
GREECE
Owners History
Title Instruments
Payments history
13 renewals have been done
© OBI all rights reserved
designed & developed by PROFILE S.A.
Certified QMS :
EN ISO 9001:2015
and
ΕΝ ISO 14001:2015
The project "Internet technological information diffusion from industrial property titles" is co-financed 70% by the European Regional Development Found and 30% by the Hellenic public sector (Operational programme "Competitiveness", Measure 4.4).